Antihypertensive action of allantoin in animals

Mei Fen Chen, Jo Ting Tsai, Li Jen Chen, Tung Pi Wu, Jia Jang Yang, Li Te Yin, Yu Lin Yang, Tai An Chiang, Han Lin Lu, Ming Chang Wu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamic d P / d t max significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.

Original languageEnglish
Article number690135
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Allantoin
Antihypertensive Agents
Animals
Rats
Blood pressure
efaroxan
Guanidine
Hemodynamics
Blood Pressure
Imidazoline Receptors
Imidazolines
Derivatives
Tail
Pathologic Constriction
Blood
Heart Rate
Hypertension

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Chen, M. F., Tsai, J. T., Chen, L. J., Wu, T. P., Yang, J. J., Yin, L. T., ... Wu, M. C. (2014). Antihypertensive action of allantoin in animals. BioMed Research International, 2014, [690135]. https://doi.org/10.1155/2014/690135

Antihypertensive action of allantoin in animals. / Chen, Mei Fen; Tsai, Jo Ting; Chen, Li Jen; Wu, Tung Pi; Yang, Jia Jang; Yin, Li Te; Yang, Yu Lin; Chiang, Tai An; Lu, Han Lin; Wu, Ming Chang.

In: BioMed Research International, Vol. 2014, 690135, 2014.

Research output: Contribution to journalArticle

Chen, MF, Tsai, JT, Chen, LJ, Wu, TP, Yang, JJ, Yin, LT, Yang, YL, Chiang, TA, Lu, HL & Wu, MC 2014, 'Antihypertensive action of allantoin in animals', BioMed Research International, vol. 2014, 690135. https://doi.org/10.1155/2014/690135
Chen, Mei Fen ; Tsai, Jo Ting ; Chen, Li Jen ; Wu, Tung Pi ; Yang, Jia Jang ; Yin, Li Te ; Yang, Yu Lin ; Chiang, Tai An ; Lu, Han Lin ; Wu, Ming Chang. / Antihypertensive action of allantoin in animals. In: BioMed Research International. 2014 ; Vol. 2014.
@article{c3139c5be43841149a90f798a7ba8883,
title = "Antihypertensive action of allantoin in animals",
abstract = "The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamic d P / d t max significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.",
author = "Chen, {Mei Fen} and Tsai, {Jo Ting} and Chen, {Li Jen} and Wu, {Tung Pi} and Yang, {Jia Jang} and Yin, {Li Te} and Yang, {Yu Lin} and Chiang, {Tai An} and Lu, {Han Lin} and Wu, {Ming Chang}",
year = "2014",
doi = "10.1155/2014/690135",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Antihypertensive action of allantoin in animals

AU - Chen, Mei Fen

AU - Tsai, Jo Ting

AU - Chen, Li Jen

AU - Wu, Tung Pi

AU - Yang, Jia Jang

AU - Yin, Li Te

AU - Yang, Yu Lin

AU - Chiang, Tai An

AU - Lu, Han Lin

AU - Wu, Ming Chang

PY - 2014

Y1 - 2014

N2 - The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamic d P / d t max significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.

AB - The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamic d P / d t max significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.

UR - http://www.scopus.com/inward/record.url?scp=84897476889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897476889&partnerID=8YFLogxK

U2 - 10.1155/2014/690135

DO - 10.1155/2014/690135

M3 - Article

C2 - 24745022

AN - SCOPUS:84897476889

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 690135

ER -